Gossamer Bio announced that its board selected a 1-for-80 reverse stock split ratio for its common stock. The transaction is expected to become effective on September 10, 2026, at 11:59 p.m. Eastern Time, with split-adjusted trading beginning on the Nasdaq Global Select Market on September 11, 2026. This action aims to regain compliance with Nasdaq's minimum bid price requirement. Concurrently, authorized common shares will decrease from 4 billion to 50 million, and total authorized capital stock will reduce from 4.07 billion to 120 million. Fractional shares will be rounded up to the nearest whole share rather than paid in cash. The company is a clinical-stage biopharmaceutical firm developing seralutinib for pulmonary arterial hypertension.
